Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives.

Date publication

mars 2016

Journal

Current opinion in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine

Tous les auteurs :
Antoni D, Mornex F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26848885

Résumé

The treatment of locally advanced nonsmall cell lung cancer (NSCLC) is becoming a significant challenge because of a growing proportion of patients with unresectable or potentially eligible for surgery after a multimodality treatment, stage II to III disease. Despite a multimodality approach consisting in concurrent chemoradiotherapy, the prognosis remains poor.

Mots clés

Antineoplastic Agents, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, Non-Small-Cell Lung, mortality, Chemoradiotherapy, methods, Combined Modality Therapy, methods, Humans, Immunotherapy, methods, Lung Neoplasms, mortality, Molecular Targeted Therapy, methods

Référence

Curr Opin Oncol. 2016 Mar;28(2):104-9